Novel cytokine–antibody fusion protein, N-820, to enhance the functions of ex vivo expanded natural killer cells against Burkitt lymphoma

BACKGROUND: The prognosis of patients with relapsed or progressive B cell (CD20(+)) non-Hodgkin’s lymphoma (B-NHL), including Burkitt lymphoma (BL), is dismal due to chemoradiotherapy resistance. Novel therapeutic strategies are urgently needed. N-820 is a fusion protein of N-803 (formerly known as...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, Yaya, Nayyar, Gaurav, Kham Su, Nang, Rosenblum, Jeremy M, Soon-Shiong, Patrick, Lee, John, Safrit, Jeffrey T, Barth, Matthew, Lee, Dean, Cairo, Mitchell S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592258/
https://www.ncbi.nlm.nih.gov/pubmed/33109629
http://dx.doi.org/10.1136/jitc-2020-001238

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592258/
https://www.ncbi.nlm.nih.gov/pubmed/33109629
http://dx.doi.org/10.1136/jitc-2020-001238

Ejemplares similares